The core of brain-computer interfaces (BCIs) lies in bidirectional interaction, involving stages from signal acquisition and processing to feature extraction and feedback control. On November 13, at the 5th Nandujiang Smart Healthcare and Rehabilitation Industry Summit Forum, Cao Lu, CTO of Hangzhou XuZhiShi Technology Co., Ltd., introduced the company's engineering prototypes, R&D roadmap, and commercialization considerations for immersive BCIs under the theme "Non-Invasive Brain-Computer Interfaces: Decoding Emotion and Cognition, Reshaping Brain Health."
Cao stated that, aligned with the definition of BCIs, XuZhiShi’s approach involves using virtual reality (VR) scenarios to create a unified environment for inducing specific brain states in patients. Signals are then acquired and processed in these induced states, followed by feature extraction and analysis. Based on decoding results, dynamic adjustments are made, leading to subsequent induction and modulation steps, ultimately forming a closed loop.
Brain signal decoding varies in focus. Cao noted that some approaches emphasize motor imagery, while others focus on language, converting neural activity into text. Cognitive and emotional decoding require greater patient collaboration, integrating neural activity features, task events, and behavioral performance.
The diagram on the right illustrates the redesigned closed-loop system, spanning induction, decoding, and modulation. Cao emphasized that the company primarily develops integrated hardware devices, with the core philosophy being "breaking down single-technology silos." The EEG component focuses on applications of new pathways. Their workflow begins by creating a unified environment in a virtual world, which stably induces patient states, followed by real-time modulation.
Why is virtual reality essential?
Cao explained that it enables precise induction. The brain's response to stimuli is state-dependent, exhibiting stimulus dependency; additionally, some BCIs undergo changes after training. Therefore, clear tasks and setups are required. EEG acquisition is used to determine whether patients have entered the corresponding state, followed by modulation through various means. This involves three aspects: brain state recognition via signal analysis; collaborative intervention using VR tasks; and closed-loop optimization, where intervention does not end immediately but continues, returning to sustained induction and intervention.
He summarized state-dependent precise modulation with three terms: selecting the state, selecting the timing, and selecting the dosage. Attention must be paid not only to how stimuli are arranged but also to measurement feedback after stimulation stops, to determine if the brain produces a sustained response. Cao outlined XuZhiShi’s R&D roadmap in four stages: starting from measurement, moving to fusion, then to closed-loop systems, and finally to adaptive systems. In terms of data dimensions, the hierarchy ranges from top to bottom as strongly labeled data. XuZhiShi was selected as a National Specialized, Refined, Distinctive, and Innovative (SRDI) enterprise in 2025, holds over 80 patents and software copyrights, and has collaborated with more than 1,000 institutions.
Considering the company’s development, XuZhiShi’s current focus is on immersive BCIs, with Class III medical device certification for BCI products soon entering clinical trials. Beyond medical device certifications, the company has accumulated technologies including non-invasive BCI research for depression, as well as sleep and cognitive rehabilitation. The equipment already approved and currently under production forms a full-scenario closed loop, covering diagnosis, rehabilitation, and focused treatment. Among partner institutions, Cao mentioned Peking University Sixth Hospital, among others. The company team includes three academicians, seven clinical experts, and four technical advisors.
Commercialization pathways represent another key focus. Cao raised the question: How long will it take for BCIs to enter the consumer-grade market? The main issue lies in choosing between "making candy-coated pills" or "making actual medicine"—whether to first enter the consumer market to achieve widespread adoption or to prioritize therapeutic efficacy and address essential medical needs. XuZhiShi’s current strategy is to first focus on pediatric neurodevelopmental psychology and neurorehabilitation, establishing clinical evidence and service capabilities in hospitals, and then gradually extend services from hospitals to homes.
In overseas markets, the company has signed strategic agreements with partners in the Middle East. Cao stated that the primary priority for the next five years is clinical penetration: demonstrating therapeutic efficacy before building foundational platforms. The company’s vision is to expand the digital dimension of life, and its mission is to benefit human brain health.